Needham Reiterates Buy on Cogent Biosciences, Maintains $22 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Cogent Biosciences (NASDAQ:COGT) and maintained a price target of $22.
August 09, 2023 | 7:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Cogent Biosciences and maintained a price target of $22.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $22 price target could potentially boost investor confidence in Cogent Biosciences, leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100